Received May 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Tiredness; Depressed mood; body aches/ pain all over; the patient has not yet received her second Shingrix dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of tiredness in an adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. The patient did not receive the 2nd dose of Shingrix. On an unknown date, 4 days after receiving Shingrix, the patient experienced tiredness (Verbatim: Tiredness), depressed mood (Verbatim: Depressed mood), general body pain (Verbatim: body aches/ pain all over) and incomplete course of vaccination (Verbatim: the patient has not yet received her second Shingrix dose). The outcome of the tiredness, depressed mood and general body pain were resolved and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the tiredness, depressed mood and general body pain to be related to Shingrix. It was unknown if the company considered the tiredness, depressed mood and general body pain to be related to Shingrix. Additional Information: GSK Receipt date: 22-APR-2026 The patient received first Shingrix vaccine nearly two years ago, in 2024. The batch number was not provided upon follow up with the reporter.